Trial · NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
NCT07002216, Phase 2, Recruiting, University of Miami
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma. Trials, record NCT07002216. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07002216
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
- NCT number
- NCT07002216
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- University of Miami
- Conditions
- Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, Dexamethasone
- First posted
- 2025-06-03
- Last updated
- 2025-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 12 months | Progression-free survival (PFS) is defined as the elapsed time in months from the start of treatment until disease progression or death, whichever is earlier. Follow-up times for participants who remain alive without progression will be censored at the last documented disease assessment date. |
| Secondary | Progression-free survival (PFS) | Up to 24 months | Progression-free survival (PFS) is defined as the elapsed time in months from the start of treatment until disease progression or death, whichever is earlier. Follow-up times for participants who remain alive without progression will be censored at the last documented disease assessment date. |
| Secondary | Number of Treatment-Related Adverse Events (AEs) | Up to 40 months | The number of treatment-related AEs will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Standard definitions for seriousness will be applied. |
| Secondary | Number of Treatment-Related Serious Adverse Events (SAEs) | Up to 40 months | The number of treatment-related SAEs will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Standard definitions for seriousness will be applied. |
| Secondary | Percentage of Participants With Toxicity Throughout BrECADD Measured by PRO-CTCAE | Up to 40 months | Toxicity will be measured by the percentage of participants using the Participant Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE). This criteria is a measurement system designed by the National Cancer Institute (NCI) to capture and evaluate the symptomatic side effects experienced by cancer patients during clinical trials, allowing patients to self-report on the frequency, severity, interference, and presence/absence of symptoms like pain, fatigue, nausea, and skin reactions, providing a more patient-centric perspective on treatment toxicity compared to clinician-based assessments alone. |
| Secondary | Percentage of Participants With Toxicity Throughout BrECADD measured by FRAIL | Up to 40 months | Toxicity will be measured by the percentage of participants using the Fatigue, Resistance, Aerobic Capacity, Illnesses and Loss of Weight (FRAIL) questionnaire. The FRAIL scale (short five-questions assessment of fatigue, resistance, aerobic capacity, illnesses and loss of weight) classified the patients into three categories: robust (score=0), pre-frailty (score=1-2), and frailty (score=3-5) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07002216
GET https://conductscience.org/api/trials/v1/NCT07002216/registered